Navigation Links
ACORN CRO Continues Growth in Strong Third Quarter
Date:11/10/2008

Oncology Focused Contract Research Organization Exceeds Expectations

MEMPHIS, Tenn., Nov. 10 /PRNewswire/ -- ACORN CRO, a Contract Research Organization exclusively focused on oncology, announced today that its third quarter had once again exceeded projections as the company continues to experience banner growth. "The industry has responded favorably to ACORN's ability to consistently exceed client expectations, and we are ahead of projections in both number of projects, patients accrued, and revenue generated. Our strong, active relationship with community oncology and its physicians along with our proprietary technology provide sponsors with a combination for success," remarked Steve Coplon, ACORN CEO.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081110/CLM032LOGO )

ACORN CRO currently provides services for both specific cancer types and supportive care studies with additional projects ready to launch in the near future. Positioned for continued growth in 2009, ACORN CRO has expanded its staff and capabilities. ACORN CRO's experienced team provides sponsors with Project and Site Management; Data Management via Guardian EDC(TM); Statistics and Statistical Programming; and Medical and Scientific Writing.

Founded in community oncology and grounded with the most stringent scientific disciplines, ACORN CRO seamlessly incorporates the best of both worlds. "Though ACORN operates with a strong business model focused on operational success, scientific excellence guides our organization," according to Dr. Lee Schwartzberg, President and Chief Medical Director. Nationally recognized for his commitment to research at the community level, Dr. Schwartzberg co-founded Accelerated Community Oncology Research Network (ACORN), enabling oncologists nationwide to provide their patients the most promising research initiatives.

ACORN CRO evolved in response to sponsor requests for value-driven quality solutions and accelerated patient accruals. With a team approach, ACORN CRO lends itself to highly efficient and accurate trial operations. Close working relationships with community oncology practices enable prompt accruals.

"The trajectory of ACORN CRO for 2009 portends the most successful year for our company," stated Coplon. "We look forward to seeing sponsors at various meetings to showcase our abilities."

For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

ACORN CRO

ACORN CRO is a full-service, oncology-focused contract research organization, providing value-driven, quality solutions to the pharmaceutical and biotech industry and offering unparalleled customer service in monitoring; clinical data management; statistical analysis; medical writing and project management. ACORN CRO delivers insights from key oncology opinion leaders and accelerates the research process through advanced levels of efficiency.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055 x1312

dcoble@sosacorn.com


'/>"/>
SOURCE ACORN CRO
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development
2. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
3. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
4. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
5. ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results
6. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
7. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
8. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
9. Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis?
10. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
11. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):